Prospective comparison of ARNi With ACE-I to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF): Paragon of a study or further investigation paramount?

Circulation

Volumn 131, Issue 1, 2015, Pages 11-12

  Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin receptor blocker; Editorials; Heart failure; Natriuretic peptide

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; 3-(1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-3'-METHYL-2'-(PENTANOYL(2'-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); EDITORIAL; FOLLOW UP; HEART FAILURE; HUMAN; MORBIDITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; DISEASE COURSE;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; ENALAPRIL; HEART FAILURE; HUMANS; NEPRILYSIN; TETRAZOLES;

EID: 84925581946     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013887     Document Type: Editorial

References (9)

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
2. Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau, JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen C-H, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim K-S, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJA, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Ching-Chiew Wong R, on behalf of the PARADIGM-HF Investigators and Coordinators. Angiotensin-neprilysin inhibition and clinical progression in surviving patients with heart failure. Circulation 2015;131:54-61.
3. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
4. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
5. Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005;315:1306-1313.
6. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315-320.
7. Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci. 2013;5:98.
8. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
9. Hopper I, Bodey F, Krum H. Neprilysin inhibitors preserve renal function in heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol. 2014; In press.